Advertisement

CNS Drugs

, Volume 32, Issue 4, pp 367–376 | Cite as

Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims

  • Fang-Ju Lin
  • Hung-Wei Lin
  • Yunn-Fang Ho
Original Research Article
  • 103 Downloads

Abstract

Background

Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited.

Objective

The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose intensity, and risk of developing PSE were investigated by studying Taiwanese health claims (2003–2013).

Methods

Patients with new-onset ischaemic stroke were identified. The main outcome was a diagnosis of epilepsy after ischaemic stroke. According to pre-stroke statin use, groups of current users, former users, and non-users were compared using ANOVA. An extended Cox regression model was utilized to estimate the hazard ratio (HR) of PSE, with post-stroke statin use and certain comedications as time-dependent variables. Serial sensitivity analyses were performed to ensure study robustness.

Results

Of the 20,858 ischaemic stroke patients, 954 (4.6%) developed PSE. Post-stroke statin use (adjusted HR (aHR) 0.55; 95% confidence interval 0.46–0.67, p < 0.001), but not pre-stroke statin use was associated with a significantly reduced risk of developing PSE. A dose-response correlation was also observed between PSE risk reduction and quartiles of the statin cumulative defined daily dose (cDDD) (aHR 0.84, 0.67, 0.53, and 0.50 for the lowest, second, third, and highest quartiles of cDDD, respectively). Risk predictors and protectors against PSE were also characterized.

Conclusion

The post-stroke use of statins after ischaemic stroke was associated with PSE risk reduction in a cDDD-dependent manner. Further clinical studies on the potential applications of statins for PSE prophylaxis, particularly among at-risk patients, are warranted.

Notes

Compliance with Ethical Standards

This study was based on healthcare data from the National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare, and previously managed by the National Health Research Institutes. The data founders and providers had no role in the study design, data analysis, data interpretation, or writing of the report.

Conflict of interest

Fang-Ju Lin, Hung-Wei Lin, and Yunn-Fang Ho declare no conflicts of interest.

Funding

No funding was received for the study.

Supplementary material

40263_2018_501_MOESM1_ESM.docx (31 kb)
Supplementary material 1 (DOCX 30 kb)

References

  1. 1.
    Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol. 2002;59:195–201.CrossRefPubMedGoogle Scholar
  2. 2.
    Jungehulsing GJ, Heuschmann PU, Holtkamp M, Schwab S, Kolominsky-Rabas PL. Incidence and predictors of post-stroke epilepsy. Acta Neurol Scand. 2013;127:427–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen TC, Chen YY, Cheng PY, Lai CH. The incidence rate of post-stroke epilepsy: a 5-year follow-up study in Taiwan. Epilepsy Res. 2012;102:188–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Guo J, Guo J, Li J, et al. Statin treatment reduces the risk of poststroke seizures. Neurology. 2015;85:701–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke. 2004;35:1769–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Lamy C, Domigo V, Semah F, et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology. 2003;60:400–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.CrossRefPubMedGoogle Scholar
  8. 8.
    Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S1–45.CrossRefPubMedGoogle Scholar
  9. 9.
    McFarland AJ, Anoopkumar-Dukie S, Arora DS, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15:20607–37.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Vaughan CJ, Delanty N, Basson CT. Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS Drugs. 2001;15:589–96.CrossRefPubMedGoogle Scholar
  11. 11.
    Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Zacco A, Togo J, Spence K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003;23:11104–11.CrossRefPubMedGoogle Scholar
  13. 13.
    Seker FB, Kilic U, Caglayan B, et al. HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS. Neuroscience. 2015;284:349–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Etminan M, Samii A, Brophy JM. Statin use and risk of epilepsy: a nested case–control study. Neurology. 2010;75:1496–500.CrossRefPubMedGoogle Scholar
  15. 15.
    Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a national health insurance claims database. J Formos Med Assoc. 2015;114:254–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Jette N, Beghi E, Hesdorffer D, et al. ICD coding for epilepsy: past, present, and future—a report by the International League Against Epilepsy Task Force on ICD codes in epilepsy. Epilepsia. 2015;56:348–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Chang CH, Lin CH, Caffrey JL, et al. Risk of intracranial hemorrhage from statin use in Asians: a nationwide cohort study. Circulation. 2015;131:2070–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Sung SF, Hsieh CY, Yang YHK, et al. Developing a stroke severity index based on administrative data was feasible using data mining techniques. J Clin Epidemiol. 2015;68:1292–300.CrossRefPubMedGoogle Scholar
  19. 19.
    Sung SF, Hsieh CY, Lin HJ, et al. Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. BMC Health Serv Res. 2016;16:509.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269–75.CrossRefPubMedGoogle Scholar
  21. 21.
    De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci. 2000;12:2623–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Gouveia TL, Scorza FA, Iha HA, et al. Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy. Epilepsy Behav. 2014;36:68–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Lossius MI, Ronning OM, Slapo GD, Mowinckel P, Gjerstad L. Poststroke epilepsy: occurrence and predictors—a long-term prospective controlled study (Akershus Stroke Study). Epilepsia. 2005;46:1246–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhao RR, Xu XC, Xu F, et al. Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. Biochem Biophys Res Commun. 2014;448:414–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Pugh MJ, Knoefel JE, Mortensen EM, Amuan ME, Berlowitz DR, Van Cott AC. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc. 2009;57:237–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Graham NS, Crichton S, Koutroumanidis M, Wolfe CD, Rudd AG. Incidence and associations of poststroke epilepsy: the prospective South London Stroke Register. Stroke. 2013;44:605–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Huang CW, Saposnik G, Fang J, Steven DA, Burneo JG. Influence of seizures on stroke outcomes: a large multicenter study. Neurology. 2014;82:768–76.CrossRefPubMedGoogle Scholar
  29. 29.
    Al-Khaled M, Matthis C, Eggers J. Statin treatment in patients with acute ischemic stroke. Int J Stroke. 2014;9:597–601.CrossRefPubMedGoogle Scholar
  30. 30.
    Xu T, Yu X, Ou S, Liu X, Yuan J, Chen Y. Statin adherence and the risk of stroke: a dose-response meta-analysis. CNS Drugs. 2017;31:263–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Curtis M, Deng Y, Lee VV, et al. Effect of dose and timing of preoperative statins on mortality after coronary artery bypass surgery. Ann Thorac Surg. 2017;104:782–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Ferlazzo E, Gasparini S, Beghi E, et al. On behalf of Epilepsy Study Group of the Italian Neurological Society. Epilepsy in cerebrovascular diseases: review of experimental and clinical data with meta-analysis of risk factors. Epilepsia. 2016;57:1205–14.CrossRefPubMedGoogle Scholar
  33. 33.
    Xie C, Sun J, Qiao W, et al. Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy. PLoS One. 2011;6:e24966.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol. 2012;65:1171–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Cheng C-L, Kao YHY, Lin S-J, Lee C-H, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Sung S-F, Hsieh C-Y, Lin H-J, Chen Y-W, Kao YHY, Li C-Y. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol. 2016;215:277–82.CrossRefPubMedGoogle Scholar
  37. 37.
    Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Graduate Institute of Clinical Pharmacy, College of MedicineNational Taiwan UniversityTaipeiTaiwan
  2. 2.School of Pharmacy, College of MedicineNational Taiwan UniversityTaipeiTaiwan
  3. 3.Department of PharmacyNational Taiwan University HospitalTaipeiTaiwan

Personalised recommendations